RE:RE:RE:stock price after CSA green ligth...10/15/20?? OpinionsI don't think anybody believes that biocloud won't get CSA approval, it should be priced in, but of course the stock will react short term to almost any news. The bigger deal is the estavloshement of the devices sensitivity. As for orders, they can't take small orders, its not economical, whether it's for a pilot study or full on deployment. The first order will be large-ish. Once the first large order comes in, it may provide working capital to start taking smaller orders, fivesies and tensors where smaller operators can do their own pilot studies. I think this is a binary situation, if it gets off the ground, they will almost certainly get 50m plus in orders in short order. Or they get zero orders at all. As for which outcome is more likely, who will criticize a government official for putting in a $50m order for this local invention with data to back them up when they're being criticized everyday for their pandemic response. Let's get this ball rolling, politicians are already drafting tweets to announce this.
felker04 wrote: I believe the same, we may actually a little bump after CSA approval, but we would actually a real significant drop if it was not.
The market already has mainliy integrated the fact that CSA would approve.
The real game changer are actual contracts with numbers.
And there is a wide range of possibility considering the potential market,
We could be looking at local pilot tests kind of contracts that would be limited in scope or large school, provincial or federal government type of contracts.